Investigational Drug Information for Demcizumab
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Demcizumab?
Demcizumab is an investigational drug.
There have been 6 clinical trials for Demcizumab.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2015.
The most common disease conditions in clinical trials are Pancreatic Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are OncoMed Pharmaceuticals, Inc., Celgene Corporation, and Novotech (Australia) Pty Limited.
There are three US patents protecting this investigational drug and fifty-two international patents.
Summary for Demcizumab
| US Patents | 3 |
| International Patents | 52 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2015-02-01) |
| Vendors | 0 |
Recent Clinical Trials for Demcizumab
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors | Celgene Corporation | Phase 1 |
| A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors | OncoMed Pharmaceuticals, Inc. | Phase 1 |
| Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma | Celgene Corporation | Phase 2 |
Clinical Trial Summary for Demcizumab
Top disease conditions for Demcizumab
Top clinical trial sponsors for Demcizumab
US Patents for Demcizumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Demcizumab | See Plans and Pricing | Binding-triggered transcriptional switches and methods of use thereof | The Regents of the University of California (Oakland, CA) | See Plans and Pricing |
| Demcizumab | See Plans and Pricing | Cell culture medium | LA JOLLA BIOLOGICS, INC. (San Diego, CA) | See Plans and Pricing |
| Demcizumab | See Plans and Pricing | Meditopes and meditope-binding antibodies and uses thereof | City of Hope (Duarte, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Demcizumab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Demcizumab | Australia | AU2011312106 | 2030-10-08 | See Plans and Pricing |
| Demcizumab | Australia | AU2012321301 | 2030-10-08 | See Plans and Pricing |
| Demcizumab | Australia | AU2017203871 | 2030-10-08 | See Plans and Pricing |
| Demcizumab | Australia | AU2019283789 | 2030-10-08 | See Plans and Pricing |
| Demcizumab | Australia | AU2021215122 | 2030-10-08 | See Plans and Pricing |
| Demcizumab | Canada | CA2814040 | 2030-10-08 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
